Company: HSDTW
Filing Date: 2025-04-22
Form Type: 8-K
Source: 0001558370-25-005150
Chunk: 1

Company: Solana Co
Filing Date: 2025-04-22
Form: 8-K
Item: Item 5.07
Chunk 1
---
  

Proposal 3: Approval of, pursuant to Nasdaq listing rules, the issuance of up to 6,213,888 shares of our common stock upon the exercise of existing Series C and Series D warrants to purchase common stock issued to warrantholders in connection with the Warrant Exercise and Inducement Letters dated January 21, 2025 (the “ Warrant Inducement Share Issuance”):

  Votes For      Votes Against      Abstain         Broker  
                                                            
                                                 Non-Votes  
 ────────────────────────────────────────────────────────────
    808,431             72,211      151,496      1,667,373  

Proposal 4: Approval of an amendment to the Company’s Certificate of Incorporation to effect a reverse split of the outstanding Class A common stock at a ratio of 1 for 2 to 1 for 30 to be determined at the discretion of the Board of Directors, whereby each outstanding 2 to 30 shares would be combined, converted and changed into 1 share of Class A common stock, to enable the Company to comply with the Nasdaq Stock Market’s continued listing requirements (the “ Reverse Stock Split”):

  Votes For      Votes Against      Abstain         Broker  
                                                            
                                                 Non-Votes  
 ────────────────────────────────────────────────────────────
  2,397,720            301,403          388              0  

Proposal 5: Approval to authorize one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposals 3 or 4 described above:

  Votes For      Votes Against      Abstain         Broker  
                                                            
                                                 Non-Votes  
 ────────────────────────────────────────────────────────────
    985,514             45,642          982      1,667,373  

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                             HELIUS MEDICAL TECHNOLOGIES, INC.                                                        
  Dated: April 22, 2025      By:                                    /s/ Jeffrey S. Mathiesen                          
                                                                    Jeffrey S. Mathiesen                              
                                                                    Chief Financial Officer, Treasurer and Secretary